RedHill Biopharma (RDHL) Receivables - Notes (2025)

RedHill Biopharma's (RDHL) quarterly Receivables - Notes came in at $33000.0 in Q4 2025.

RedHill Biopharma (RDHL) Receivables - Notes (2025) Analysis & Trends

RedHill Biopharma (RDHL) has 1 years of Receivables - Notes data on file, last reported at $33000.0 in Q4 2025.

  • On a quarterly basis, Receivables - Notes changed N/A year-over-year to $33000.0 in Q4 2025; TTM through Dec 2025 was $33000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $33000.0, changed N/A from the prior year.
  • Receivables - Notes for Q4 2025 stood at $33000.0.
  • Over the last five years, Receivables - Notes for RDHL reached as high as $33000.0 in Q4 2025 and fell as low as $33000.0 in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 87.22 Bn 85.35 Bn -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn
10 RedHill Biopharma 640,064.98 640,064.98 -

Historic Data

Download Data
DateValue
Dec 31, 2025 33,000.00